国家药品不良反应监测年度报告(2022年)  

Annual report of national adverse drug reaction monitoring(2022)

出　　处：《中国药物警戒》2023年第6期712-719,共8页Chinese Journal of Pharmacovigilance

摘　　要：目的全面、客观地分析2022年我国药品不良反应监测情况,提示公众安全合理用药。方法总结2022年国家药品不良反应监测工作,对2022年1月1日至2022年12月31日全国药品不良反应监测网络收到的报告进行统计分析,并作出解读。结果2022年共收到药品不良反应/事件报告202.3万份。其中新的和严重药品不良反应/事件报告64.2万份;涉及怀疑药品218.5万例次,其中化学药品占82.3%、生物制品占2.6%、中药占12.8%;涉及基本药物报告94.2万份。关注抗感染药、心血管系统用药、抗变态反应药、儿童用药的不良反应发生风险。结论应持续加强药品不良反应监测工作,提高安全用药水平,更好地保障公众用药安全。Objective To analyze the amount of monitoring of adverse drug reactions/events(ADR/AE)in depth in China in 2022,and to remind the public of the need to use drugs safely and properly.Methods Work related to nation-wide monitoring of adverse drug reactions in 2022 was summarized.Reports of ADRs/AEs received by the National Adverse Drug Reaction Monitoring System in 2022 were statistically analyzed and interpreted.Results A total of 2.023 million reports of ADR/AE were received in 2022,642000 of which were new and serious reports.2.185 million reports involved suspected drugs,82.3%of which were chemical drugs,2.6%were biological products,and 12.8%were Chinese medicines.There were 942000 reports of ADR/AE that involved essential drugs.The risks of adverse reactions of anti-infective drugs,cardiovascular system drugs,anti-metabolic drugs,and drugs for children were given much attention.Conclusion Adverse drug reaction monitoring should continue to be strengthened to ensure safe use of drugs and offer better protection for the public.

关 键 词：药品不良反应/事件 监测 抗感染 心血管 抗变态反应 儿童 风险控制 年度报告 

分 类 号：R994.11[医药卫生—毒理学]